COMPARE · Data as of August 21, 2026
ANIP vs HRMY
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 79.6, HRMY scored 88.7 — HRMY leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
79.6
$77.32 · $1.8B
fundamentals as of
Score gap
9.1
HRMY leads
HRMY
Harmony Biosciences Holdings, Inc.
88.7
$38.07 · $2.2B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHRMY12.3x
- Fastest growthANIP+30.9%
- Strongest balance sheetHRMY0.16
- Highest qualityHRMY80 / 100
- Largest discount to fair valueHRMY-75%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
HRMY
66
Qualityreturns · margins · balance sheet
80
94
Growthrevenue & earnings expansion
91
81
Valuevaluation vs sector peers
95
HRMY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ANIP
HRMY
$173mC
FCF
$355mC
+30.9%A
Rev
+24.3%A-
1.05C
D/E
0.16B+
16.8xA-
P/E
12.3xA
1.26B
PEG
0.44A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
HRMY
44% below
Price vs fair valuelower is cheaper
75% below
~-6%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-18%/yr
+58%
1-yr DCF upside
+207%
+80%
5-yr DCF upside
+304%
+118%
10-yr DCF upside
+507%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
HRMY
Why this score
- Durable high returns
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.8b. Down 22% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +40% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.2b. 7% off the 52-week high of $40.87. Revenue growing +24%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +21% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
The model favors HRMY (90.7) over ANIP (83.9) due to its stronger Quality pillar score of 80 versus ANIP's 64, reinforced by a "Durable high returns" signal. A contrarian might still prefer ANIP, as its implied growth of -8% per year suggests less pessimism is priced in than HRMY's -18% per year. Both stocks are trading significantly below their DCF fair values.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and HRMY diverge
On the headline score the gap is 9.1 points in favor of HRMY. The widest single difference is Value, where HRMY leads by 14.2 points.
- ValueANIP 81.2 · HRMY 95.4HRMY +14.2
- QualityANIP 66.2 · HRMY 79.9HRMY +13.7
- GrowthANIP 93.8 · HRMY 91.5level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.